Evolving Thrombolytics: from Alteplase to Tenecteplase

Miller, Samantha; Warach, Steven

doi:10.1007/s13311-023-01391-3

Cited by 10 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the second generation, they have a lower risk of systemic hemorrhage. In the treatment of acute ischemic stroke, compared with alteplase, the use of teneplase can reduce the incidence of cerebral hemorrhage [25][26][27]. The pharmaceutical formulations that can be directly used for thrombolysis are still under research and development.…”

Section: Clinical Treatment Of Thrombotic Diseasesmentioning

confidence: 99%

Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery

Ren,

Mi,

Wei

et al. 2024

Molecules

View full text Add to dashboard Cite

Thrombotic disease has been listed as the third most fatal vascular disease in the world. After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of adverse reactions such as bleeding. A number of studies have shown that the application of various nano-functional materials in thrombus-targeted drug delivery, combined with external stimuli, such as magnetic, near-infrared light, ultrasound, etc., enrich the drugs in the thrombus site and use the properties of nano-functional materials for collaborative thrombolysis, which can effectively reduce adverse reactions such as bleeding and improve thrombolysis efficiency. In this paper, the research progress of organic nanomaterials, inorganic nanomaterials, and biomimetic nanomaterials for drug delivery is briefly reviewed.

show abstract

Section: Clinical Treatment Of Thrombotic Diseasesmentioning

confidence: 99%